AVNR Insider Trading Activity and SEC Form 4 Filings
AVNR insider trading summary
No open-market insider purchases or sales of Avanir Pharmaceuticals, Inc. (AVNR) have been reported on SEC Form 4 in the past 12 months.
Latest AVNR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 18, 2014 | Joao MD Siffert | SVP, R&D | Sell | $262K (15,505 @ $16.93) |
| Dec 18, 2014 | Christine Ocampo | Vice President, Finance | Sell | $98K (5,780 @ $16.93) |
| Dec 17, 2014 | Keith Katkin | President and CEO | Sell | $1.1M (62,520 @ $16.93) |
| Dec 16, 2014 | Christine Ocampo | Vice President, Finance | Sell | $296K (17,500 @ $16.94) |
| Dec 16, 2014 | Christine Ocampo | Vice President, Finance | Sell | $212K (12,500 @ $16.94) |
| Dec 15, 2014 | Keith Katkin | President and CEO | Sell | $3.3M (195,160 @ $16.95) |
| Dec 15, 2014 | Keith Katkin | President and CEO | Sell | $339K (20,000 @ $16.95) |
| Nov 28, 2014 | Rohan Palekar | SVP & Chief Commercial Officer | Sell | $225K (15,000 @ $15.00) |
| Oct 24, 2014 | Keith Katkin | President and CEO | Sell | $324K (27,567 @ $11.76) |
| Oct 24, 2014 | Christine Ocampo | Vice President, Finance | Sell | $25K (2,080 @ $11.81) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.